Entry Detail



General Information

Database ID:exR0356590
RNA Name:hsa-miR-22-3p
RNA Type:miRNA
Chromosome:chr17
Starnd:-
Coordinate:
Start Site(bp):1713914End Site(bp):1713935
External Links:hsa-miR-22-3p



Disease Information

Disease Name:Breast Cancer
Disease Category:Cancers
MeSH ID:D001943
Type:Neoplasms/Breast Neoplasms
Alias:Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast



Expression Detail

GEO ID:GSE98181
Description:Circulating miRNA profiles from serum of women at high-risk for breast cancer
Experimental Design:Cancer vs Control
Case Disease Type:Breast Cancer
Case Disease SubType:NA
Case Sample:Breast Cancer
Control Sample:Healthy
Number of Case:24
Number of Control:24
Number of Samples:48





Regulatory Relationship

mRNA targets:
Gene SymbolChromosomeStart Site(bp)End Site(bp)Strand
CCDC97
chr19
41310172
41324873
+
AP1S1
chr7
101154456
101161596
+
RCOR1
chr14
102592649
102730561
+
RAB11FIP4
chr17
31391675
31538211
+
PPIF
chr10
79347469
79355334
+
FBXL19
chr16
30923055
30948783
+
FNBP4
chr11
47716494
47767443
-
DCP1A
chr3
53283429
53347586
-
GDAP1
chr8
74321130
74488872
+
WSB2
chr12
118032694
118062430
-
ITGA5
chr12
54395261
54419266
-
IRS2
chr13
109752695
109786583
-
FOXP1
chr3
70952817
71583993
-
TMEM179B
chr11
62787402
62790400
+
ETS1
chr11
128458761
128587558
-
ATP2C1
chr3
130850595
131016712
+
ZNF740
chr12
53180704
53195142
+
CACUL1
chr10
118674167
118755249
-
ATP6V0B
chr1
43974487
43978295
+
ACLY
chr17
41866917
41930542
-
CLASP1
chr2
121337776
121649587
-
PRLR
chr5
35048756
35230487
-
PDPR
chr16
70113626
70162537
+
WWC2
chr4
183099257
183320777
+
TAGLN
chr11
117199370
117207464
+
BCL9
chr1
147541501
147626216
+
GLIS2
chr16
4314761
4339597
+
GBF1
chr10
102245532
102382899
+
PDSS1
chr10
26697701
26746798
+
RANBP2
chr2
108719482
108785809
+
miRNA targets:NA
circRNA targets:
circRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
hsa_circ_0001699
chr7
40027197
40041630
+
hsa_circ_0001414
chr4
56277780
56284152
+
hsa_circ_0000733
chr17
1561546
1562030
-
lncRNA targets:
lncRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
AC021078.1
chr5
149494314
149504670
-
AL360012.1
chr1
28648600
28648730
+
MALAT1
chr11
65497688
65506516
+
NEAT1
chr11
65422774
65445540
+
NORAD
chr20
36045618
36051018
-
OIP5-AS1
chr15
41283990
41309737
+
SNHG16
chr17
76557764
76565348
+
Display:



Experiment Detail

GEO ID:GSE98181
Sample Source:Blood
Source Fraction:Serum
Platform:GPL21572
Method:Microarray
Num of detected RNA Type:1
Num of detected RNAs of this Type:2546
Sample treatment protocol:Serum is obtained from coagulated whole blood samples by centrifugation at 3000 rpm for 10 minutes.
RNA Extract protocol:RNA was isolated from a 200ul serum aliquot using the miRNeasy Serum Plasma kit with ce-miR-39 spike-in (QIAGEN), QIAcube (QIAGEN) automation, and eluted with 14uL of nuclease-free water.
RNA library preparation protocol:Exactly 8ul of RNA was tagged with a Poly-A tail, using an ATP driven reaction from the Affymetrix® FlashTag™ Biotin HSR RNA Labeling Kit.



Reference

PMID:29348816
Title:Development of a predictive miRNA signature for breast cancer risk among high-risk women.
Author:Farina NH, Ramsey JE, Cuke ME, Ahern TP, Shirley DJ, Stein JL, Stein GS, Lian JB, Wood ME
Journal:Oncotarget. 2017 Nov 28;8(68):112170-112183.
Description:We evaluated the ability of C-miRNAs to identify women most likely to develop breast cancer by profiling miRNA from serum obtained long before diagnosis.